Effects of Post-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
Biobehavioral Study of Opioid Drug Seeking Behavior: Study 2
4 other identifiers
observational
16
1 country
1
Brief Summary
The purpose of this study is to determine whether knowledge of post-session hydromorphone (HYD) availability reduces drug seeking behavior in heroin dependent individuals.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 16, 2005
CompletedFirst Posted
Study publicly available on registry
September 22, 2005
CompletedJune 5, 2012
June 1, 2012
September 16, 2005
June 1, 2012
Conditions
Keywords
Interventions
Eligibility Criteria
Heroin dependent research volunteers
You may qualify if:
- Opioid dependent, as determined by the structured clinical interview for DSM-IV (SCID) and Addiction Severity Index (ASI)
- Positive urine test for opiates
- Willing to use an adequate form of contraception for the duration of the study
- Reads and writes English
You may not qualify if:
- Psychiatric illness, as determined by the DSM-IV criteria
- History of or current neurological disease, including structural abnormalities, seizures, infection, peripheral neuropathy, and head traumas
- History of cardiovascular disease, myocardial infarction, chest pain, or edema
- Systolic blood pressure greater than 160 mm Hg or less than 95 mm Hg; PR diastolic blood pressure greater than 95 mm Hg
- Pulmonary disease, including obstructive pulmonary disease, cor pulmonale, tuberculosis, and asthma
- Systemic disease (e.g., endocrinopathies, liver or kidney failure, myxedema, hypothyroidism, Addison's disease, autoimmune disease)
- Current alcohol or sedative drug dependence
- Pregnant or breastfeeding
- Currently receiving treatment for opioid dependence
- Known phobia of injections
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Wayne State Universitylead
- National Institute on Drug Abuse (NIDA)collaborator
Study Sites (1)
Wayne State University
Detroit, Michigan, 48207, United States
Related Publications (3)
Woodcock EA, Lundahl LH, Burmeister M, Greenwald MK. Functional mu opioid receptor polymorphism (OPRM1 A(118) G) associated with heroin use outcomes in Caucasian males: A pilot study. Am J Addict. 2015 Jun;24(4):329-35. doi: 10.1111/ajad.12187. Epub 2015 Apr 24.
PMID: 25911999DERIVEDStoltman JJ, Woodcock EA, Lister JJ, Greenwald MK, Lundahl LH. Exploration of the telescoping effect among not-in-treatment, intensive heroin-using research volunteers. Drug Alcohol Depend. 2015 Mar 1;148:217-20. doi: 10.1016/j.drugalcdep.2015.01.010. Epub 2015 Jan 19.
PMID: 25630964DERIVEDGreenwald MK, Steinmiller CL, Sliwerska E, Lundahl L, Burmeister M. BDNF Val(66)Met genotype is associated with drug-seeking phenotypes in heroin-dependent individuals: a pilot study. Addict Biol. 2013 Sep;18(5):836-45. doi: 10.1111/j.1369-1600.2011.00431.x. Epub 2012 Feb 16.
PMID: 22339949DERIVED
Biospecimen
Whole Blood
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mark Greenwald, PhD
Wayne State University
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
September 16, 2005
First Posted
September 22, 2005
Study Start
August 1, 2005
Last Updated
June 5, 2012
Record last verified: 2012-06